Kanishk Kumar: Thalassemia Pipeline 2025 Addressing Hemoglobin Deficiencies in Inherited Blood Disorders
Kanishk Kumar, Digital Marketing Executive at DelveInsight Business Research LLP, shared a post on LinkedIn:
”Thalassemia Pipeline 2025: Addressing Hemoglobin Deficiencies in Inherited Blood Disorders
Thalassemia, a group of inherited blood disorders causing reduced hemoglobin synthesis and chronic anemia, is advancing with innovative therapies in 2025. The Thalassemia Pipeline features 25+ pharmaceutical firms developing 28+ investigational medications, from gene editing to small molecules, aimed at increasing hemoglobin levels, reducing transfusion dependency, and improving quality of life for patients with varying severity.
Key Developments in Thalassemia Treatment:
Etavopivat by Novo Nordisk, a PKR activator in Phase III, aims to improve red blood cell health and reduce anemia in thalassemia by enhancing oxygen affinity and decreasing hemolysis.
CS-101 by Correct Sequence Therapeutics, a gene editing therapy in Phase I, reactivates fetal hemoglobin production for a potential lifetime cure using the patient’s own stem cells.
Leading Thalassemia Companies include Novo Nordisk , Kind Pharmaceuticals LLC, Correct Sequence Therapeutics , Editas Medicine, San Rocco Therapeutics, Lantu Biopharma, Regeneron , Kanglin Biotec, Shanghai BDgene Co., Ltd., BioRay Pharmaceutical , Celgene, Mabwell , among others.
Promising therapies include Etavopivat, AND017, CS101, among others.
DelveInsight’s comprehensive report on the Thalassemia Pipeline Analysis 2025․՛՛
Stay updated with Hemostasis Today.
-
Feb 18, 2026, 15:18Veronica Sanchez: First-Ever Interventional Recommendations for Pediatric Acute Ischemic Stroke
-
Feb 18, 2026, 15:07Flora Peyvandi: The Evidence Gap in Drug Safety During Pregnancy
-
Feb 18, 2026, 14:44Omolade Awodu Awodu։ Charting a Sustainable Path for Inherited Blood Disorders in Nigeria
-
Feb 18, 2026, 14:34Vincent Ten Cate: FXI(a) and Its Links With Cardiovascular Disease
-
Feb 18, 2026, 14:30Mohamed Sikkander Abdul Razak: A Single Stem Cell Generating 14 Million Tumor-Killing NK Cells
-
Feb 18, 2026, 13:26Jecko Thachil: Are There More Than Anticoagulants for Venous Thromboembolism Prophylaxis?
-
Feb 18, 2026, 12:41Davide Bartoli: The Hidden Cost of Informal Caregiving After Stroke
-
Feb 18, 2026, 12:34Amy Goundry: Which Are The Next Major Advances in Blood and Plasma-Driven Immune Regulation?
-
Feb 18, 2026, 12:26John Monczewski: A Stroke, A Wake‑Up Call, And a Whole Lot of Gratitude